Pinteon Therapeutics logo
Menu Button
  • About Us
  • Approach
    • PNT001 program
    • Clinical strategy
  • Tauopathies
  • News

Press Releases/News

May 6, 2020

Pinteon Therapeutics Announces Scientific Advisory Board for Traumatic Brain Injury

October 31, 2019

Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease

May 6, 2020

Pinteon Therapeutics Announces Scientific Advisory Board for Traumatic Brain Injury

October 31, 2019

Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease

Media Contact

Stephanie Simon
Ten Bridge Communications
(617) 581-9333
stephanie@tenbridgecommunications.com

For all other company inquiries,
contact us at info@pinteon.com

© PINTEON 2021. All rights reserved

  • Privacy Policy

Contact Us

  • LinkedIn
  • About Us
  • Approach
    • PNT001 program
    • Clinical strategy
  • Tauopathies
  • News